Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BZAG trial of sequential bendamustine followed by obinutuzumab, zanubrutinib, and venetoclax in relapsed or refractory chronic lymphocytic leukemia
2022-502201-16-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab, zanubrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University of Cologne. Primary endpoint: Peripheral blood MRD negativity rate at final restaging. Planned start Jun 2024; status: authorised.
02
Drugs
bendamustineobinutuzumabzanubrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-502201-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502201-16-00.